Jump to Main Contents
先端医療開発センター

Home > Organization > Cancer Immunotherapy (Kashiwa) > Development of cancer vaccine therapy

Development of cancer vaccine therapy

We have practiced from basic research to translational research through the development of cancer peptide vaccine therapy, and have reported many research results. In particular, we will continue to develop glypican-3 (GPC3) and HSP105, which are original cancer antigens, in the future.

fig01.png

fig02.png